Mr. 3 has a guess about next PR. I've got one too
Post# of 153359
Quote:
The encouraging pooled survival (1 yr. 41.3%, 2 yr. 24.8%, 3 yr 19.8%) suggests further studies in patients with mTNBC are warranted.
But what if that flat ending is supposed to make us think -- well, when are we going to get another Leron vs. mTNBC study? So that's my guess about the next PR: it will announce a Phase III mTNBC trial, funded by a non-profit like Gates or Andersen or the AACR.
So that's my shot. Hoping to take that kewpie doll home with me next Thursday.

